Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233437 | 0.97 | HTR1A (0.54) | HTR1ASLC6A4MAPTDRD2HTR2A | |
| SCHEMBL5236560 | 0.89 | HTR1A (0.48) | HTR1ASLC6A4 | |
| SCHEMBL5234113 | 0.89 | HTR1A (0.48) | HTR1ASLC6A4 | |
| SCHEMBL5237424 | 0.87 | HTR1A (0.43) | HTR1ASLC6A4DRD2HTR2AHTR2C | |
| SCHEMBL5232373 | 0.86 | HTR1A (0.49) | HTR1ASLC6A4DRD2HTR2AHTR2C | |
| SCHEMBL5233106 | 0.86 | HTR1A (0.47) | HTR1ASLC6A4 | |
| SCHEMBL5235551 | 0.86 | HTR1A (0.47) | HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL5235744 | 0.86 | HTR1A (0.46) | HTR1ASLC6A4 | |
| SCHEMBL5235124 | 0.86 | HTR1A (0.46) | HTR1ASLC6A4 | |
| SCHEMBL6792078 | 0.84 | HTR1A (0.50) | HTR1ASLC6A4MAPTDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537122-B9 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-10-31 | — | — | EP | claimed |
| EP-1537122-B1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1537122-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | Wyeth (US) | 2005-06-08 | — | — | EP | claimed |
| US-6800637-B2 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-07-15 | — | — | US | claimed |
| WO-2004024734-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2004-03-25 | — | — | WO | claimed |
| EP-1537122-B9 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1537122-B1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1537122-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6800637-B2 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004024734-A1 | ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138222-A1 | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, TPH1, DBH | HTR1A 13/4885SLC6A4 42/4885MAPT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.